INBX - Inhibrx Biosciences, Inc.
About Inhibrx Biosciences, Inc. (https://inhibrx.com)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | 1967 | $2,892,473 USD |
| David Matly | President | 1986 | $911,655 USD |
| Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer | 1980 | $766,410 USD |
| Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer | 1968 | – |
| Bonne Adams | Vice President of Operations | 1977 | – |
| Carlos Bais | EVice President & Chief Scientific Officer | – | – |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer | – | – |
| Kate Burke | Vice President of Accounting | – | – |
| Leah Pollema | Vice President, General Counsel & Corporate Secretary | – | – |